Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Metformin
Drug: Melatonin
Drug: Dacarbazine

First Posted Date: 2014-07-15

Last Posted Date: 2019-11-25

Lead Sponsor: N.N. Petrov National Medical Research Center of Oncology

Target Recruit Count: 57

Registration Number: NCT02190838

Locations: 🇷🇺
N.N. Petrov Research Institute of Oncology Ambulatory Chemotherapy Department, St. Petersburg, Russian Federation
🇷🇺
N.N. Petrov Research Institute of Oncology Chemotherapy and Innovative Technologies Department, St. Petersburg, Russian Federation
🇷🇺
N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department, St.Petersburg, Russian Federation

Metformin in Psoriatic Arthritis

Not Applicable

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Placebo
Drug: Metformin

First Posted Date: 2014-07-11

Last Posted Date: 2014-07-11

Lead Sponsor: University of Alexandria

Target Recruit Count: 56

Registration Number: NCT02188654

Locations: 🇪🇬
University of Alexandria, Alexandria, Egypt

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

Phase 1

Completed

Conditions: Hyperlipidemia
Diabetes

Interventions: Drug: Metformin
Drug: Rosuvastatin
Drug: Metformin and Rosuvastatin

First Posted Date: 2014-07-10

Last Posted Date: 2018-03-29

Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT02186483

Locations: 🇰🇷
Samsung Medical Center(SMC), Seoul, Gangnam-Gu, Korea, Republic of

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Adenosquamous Lung Carcinoma
Bronchioloalveolar Carcinoma
Large Cell Lung Carcinoma
Stage IIIB Non-Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Squamous Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Recurrent Non-Small Cell Lung Carcinoma

Interventions: Radiation: Radiation Therapy
Drug: Carboplatin
Drug: Paclitaxel
Drug: Metformin

First Posted Date: 2014-07-10

Last Posted Date: 2024-05-30

Lead Sponsor: NRG Oncology

Target Recruit Count: 170

Registration Number: NCT02186847

Locations: 🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States

and more 219 locations